West Hertfordshire Hospitals MLS

NHS Trust

Department of Business Development

Hemel Hempstead General Hospital QE-Block Hillfield Road Hemel Hempstead Herts HP2 4AD

Tel No 01442 287612 Fax No 01442 287658 e-mail:andrew.moore@whht.nhs.uk

Mr Alan Pond **Director of Finance** West Hertfordshire PCT Charter House Parkway Welwyn Garden City Herts AL8 6JL

October 29, 2007

Dear Alan

Re: Disaggregation of the Block Contract

Thank you for your letter of 11th October addressed to David Law.

During the commissioning negotiations in February and March both PCT and Trust agreed that the Block Element of the SLA should be disaggregated as quickly as possible subject to being able to provide robust activity and costing information. It was enshrined in the SLA documentation that Pathology and Radiology Direct Access would be so disaggregated with effect from 1st October and to that effect shadow information has been provided on a monthly basis at practice and test level.

The Pathology element of the SLA had activity based on extrapolated data for 2005/06 with Reference costs updated for inflation. I attach a schedule detailing how this was derived from the old PCT groupings. Average unit prices were derived for this activity. The activity provided in shadow form had prices derived by Pathology from their own detailed costings at test level. It is fair to say that these unit prices have not been agreed with the PCT in advance and it is therefore proposed that the Trust revert back to those unit prices used in setting the baseline but would point out that these are average prices and we would expect to move to test prices for 2008/09 as a result of further joint working. As can be seen the activity is £31,300 higher than plan at Month 4.

I understand from John Sloan that there has been some discussion with East Herts Trust about their approach to Pathology and you have agreed that a baseline of 2004/05 would be used with average

costs and a marginal rate. Our proposal is similar in nature but uses 2005/06 as the baseline and therefore the PCT is thereby benefiting from a further year of growth in demand.

Radiology activity within the baseline of the SLA was that for 2005/06 with updated Reference Costs. The analysis by old PCT is attached together with a revised calculation based on actual activity for Months 1-4 using the test prices that generated the value within the SLA. As can be seen this produces an over-performance of £9,700 at Month 4.

The Trust agrees with your sentiment that it is important to identify whether the Block is funded correctly. However, in certain instances indicative tariffs are not available and that is why various approached were suggested as to how the PCT and the Trust could move forward. However, your suggestion that items such as LIS and IIYH are core services and therefore should not be paid separately is unacceptable. These funds cover both Trust and PCT services. They were never included in PbR Stage 3 Returns nor are they regarded as part of the SLA. Neither funding is deemed to be ongoing and so would not sit comfortably within an SLA for clinical services.

It does not make sense to suggest that the transition to full disaggregation of the Block should take place over four years. The discussion within the commissioning meetings was that the PbC groups would be consulted as to their immediate priorities for services to be moved to pay as you go. Without this change there would be no expectation that demand management initiatives would have any impact at primary care level. The Trust has yet to be advised of the outcome of these discussions.

It is not accepted that the transition from Block should be cost neutral as you suggest. The Trust is already absorbing demand changes from 2006/07 and in particular the spend on high cost drugs, again provided monthly in shadow form, bears no relation now to the level in the SLA. This area of spend is actual costs incurred and requires no detailed additional costing or apportionment. The Trust can no longer continue to fund this expenditure given that the expenditure to Month 6 of £1289k exceeds the annual allocation of £667k. An urgent resolution to this funding shortfall is required.

Given that we are already near the end of October, we need to conclude these discussions soon. I would be grateful if you could now confirm that the revised basis for Pathology and Radiology is acceptable. The Trust is happy to work with PCT colleagues throughout the remainder of this year to disaggregate the Block and it would request that you advise who should be involved from the PCT Finance Team.

Yours sincerely,

Andrew Moore Head of Business Development

c.c. Andrew Parker
Peter Jones
Beverley Flowers
Trudi Southam
Nick Evans
Phil Bradley

	Radiology West Herts	Watford	Dacorum St Albans Hertsmere Total	t Albans He	rtsmere Tota	i Tariff		Value Ta	Tariff 07/0: Value		Actual V Tests 1-4 708	Value
Code	Label	Activity						•	1	070007	808	158817.1
RBA1	Band A	8581	6493	6149 8	1027	22250 109	22.17 4 49.49	493344.80 5394.80	22.73 50.73	5529.67	4 (202.9238
RBB1	Band B1 - Mammography	2 5	14	357	ı g	1366	39.98	54609.40	40.98	55974.64	576	23602.78
RBB2	Band B2 - Maternity Ultrasound	462	2483	2718	373	9729	•	438116.33	46.16	449069.24	3544	106199 7£046 28
RBB3	Band B3 - Other Ultrasound	3133 586	1834	1807	153	4377	40.84	178760.18	41.86	183229.19	76/1	730105.36
RBB4	Band B4 - Other Band B Tests	3	3									o c
RBC1	Band C1 - Mammary Ductography / Mammography											o c
RBC2	Band C2 - Ultrasound											o C
RBC3	Band C3 - CT Pulmonary Anglography							0	5	25443 16	111	10105.04
RBC4	Band C4 - C1 Kadlomerapy Flamming	134	176	72	7	389	88.82	34549.42	40.19	14040.10	- 60	11646.12
RBC5	Band C5 - C1 Other	167		137	48	485	104.24	50556.01	106.85	51619.91	2	0
KBC	Band Co - Office Date O Tests											0
RBD1	Band D1 - C1 Band D2 - Waternity Highs Sound					;	6	7000	4004	2015 17	16	1612.133
KBUZ		7	4	თ	0	20	98.30	1906.02	200	12006 56	7	875 4418
RBD3	Band U3 - Doppler Ultrasourid	29	m	29	7	\$	122.01	12689.33	125.00	13000:30	-	0
RBD4	Band D4 - Omer band D Tests							1	100	30 702		· c
RBE1	Band E	•	-	0	0	7	289.88	579.76	297.13	594.25		o c
RBF1	Band F1 - MRI	_		ı			272.27	0.00	279.08	0.00	1	0000000
RBF2	Band F2 - Other Band F Tests	•		đ	c	15	126.70	1900.55	129.87	1948.06	ብ ;	649.3339
RBG1	Band G - Radionuclide [Isotope] Tests	- 6		, r	· c	205	166.71	34175.96	170.88		5	8714.87
RBH1	Band H - Radionuclide [Isotope] Tests	΄ α΄	5 5	3 5	· c	33	311.21	9958.71	318.99	10207.67		0
RBJ1	Band J - Radionuclide [Isotope] Tests	0		=	•	3	: !	 				
RBK1	Band K - Radionuclide [Isotope] Tests											
RBL1	Band L - Radionuclide [Isotope] Tests											
RBX1	Band M - PET Scan											
RBX2	Band X - DEXA Scan											
		13268	8 12788	11371	1656	39083		1316601.27		1349516.30		13303.00 459441.18
			ı									
					2007/08 Inflation 2.5%	ition 2.5%		32915.03				
				-	Value in Block SLA	ck SLA		1349516.30				
												000077
	Dian Month 4											449836.0

Plan Month 4

Variance

9602.41

완
뿌
_
est
-
5
•
6
റ്
중
ᆮ
∺
~~

ı



West Hertfordshire Primary Care Trust and East and North Hertfordshire Primary Care Trust

Charter House Parkway WELWYN GARDEN CITY Herts AL8 6JL

01707 361209 alan.pond@herts-pcts.nhs.uk

11th October 07

David Law
Chief Executive
West Hertfordshire Hospitals Trust
Hemel Hempstead Hospital
Hillfield Road
Hemel Hempstead
Herts Health Informatics HP2 4AD

Dear David

Re: Disaggregation of the Block Contract

I am writing in response to Andrew Moore's letter dated 7th September 2007 and the discussions at the Quarterly Review meeting of 28th September 2007.

As discussed at the Quarterly Review meeting, the PCT has a major problem with the approach suggested by the Trust. The Trust is quoting planned levels of activity against each service type and corresponding SLA values, attributed to that activity. However, it is not clear to the PCT where this information has been taken from. Activity levels and SLA values have not been agreed to this level of detail and this is precisely why we all want to disaggregate the block element of the SLA.

The figures presented by the Trust reveal some significant anomalies, e.g. in chemical pathology there is a 13% forecast underperformance on activity, but an over spend of over 100%. This is because the unit price shown under the plan is £1.68, but the actual unit price charged is £3.99.

The PCT believes that there are three objectives for this piece of work:

a) To ensure that variations in activity lead to real changes in payments due under the SLA. In this way commissioners are encouraged to

manage demand and the Trust is fairly recompensed for any increase in activity;

- To fairly value the work that the Trust undertakes and aid performance measurement by avoiding any suggestion that overspendings are the result of under funding;
- c) To aid service redesign, by avoiding perverse incentives created by the operation of the SLA.

To fulfil all three of these objectives, the whole block element of the SLA needs to be reviewed. The PCT wishes to see a fair value attributed to all the activity covered by the block element of the SLA. This would probably be by reference to the published indicative tariff or national reference costs. This value can then be compared to the total amount actually being paid to identify the amount by which the block is over or under funded. In reaching this figure, the PCT would expect other funding streams, provided historically to the Trust outside the SLA, to be taken into account. The best example of this is LIS funding which is currently supporting health informatics and related services within the Trust. The PCT view is that these are core Trust services reflected in national prices and therefore should not paid for separately again by the PCT.

Having identified the value of any over or under funding on the block element of the SLA, the PCT would propose eliminating this over a four year transition period. This is consistent with the approach to the introduction of Payment by Results and the move to the national tariff. This approach would see a premium or discount being applied, depending on whether the block element of the SLA is currently over or under funded.

An example to illustrate this is set out below. This is simplified by assuming only a single activity type and assuming inflation of 2.5% a year.

Description	Activity	Unit Price	Value	Transition Adj	Actual Payment
Baseline Block contract (Over) or Under Funded	1,000	10.00	10,000 9,500 500		
Year 1 - 2008/09	1,000	10.00	10,000	-375	9,625
Year 2 - 2009/10	1,050	10.25	10,763	-250	10,513
Year 3 - 2010/11	950	10.51	9,981	-125	9,856
Year 4 - 2011/12	1,000	10.77	10,769	0	10,769

As you can see, the unadjusted value is based on activity multiplied by price, with variations in activity being charged at the full national price. The transition adjustment is fixed regardless of changes in activity and in this case

is a discount because the baseline contract value is less than the national price.

Unfortunately what the Trust is proposing is a piecemeal disaggregation without completing this work. Added to this, the Trust's letter suggests that the activity baseline is not current and is variable in its robustness. Further work is urgently needed to achieve the vision set out by the PCT above.

To move this forward and start to achieve the objectives above, the PCT can see merits in moving some elements from block to cost per case in 2007/08, e.g. pathology and radiology. However, in the absence of the full calculations described above, the PCT is only prepared to agree to this on the basis that the move will in the first instance be cost neutral. By this the PCT means that the block element of the SLA will be reduced, for the second half of the year, by a value derived from:

recorded activity Oct-Mar 2006/07

Х

proposed unit price

In this way any variation in activity, compared to the same period last year, will lead to real changes in income to the Trust and costs to the PCT.

We need to agree a timescale for the full disaggregation work, but just as importantly, need confirmation that the approach set out above is agreed. This will help to avoid confusion or disagreement at a later date. This is the approach we have also proposed to and discussed with East and North Hertfordshire NHS Trust.

I do hope this clarifies our discussions to date and look forward to hearing from you following due consideration.

Yours sincerely

Alan Pond Director of Finance

c.c. Anne Walker
Andrew Parker
Peter Jones
Beverley Flowers
Trudi Southam

Nick Evans Phil Bradley Andrew Moore